NR3C2 and stroke disorder: Recently, a retrospective cohort study of the contemporary ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry showed that the use of MR antagonists was not associated with reduced atrial fibrillation, but showed a trend toward lower risk of stroke, transient ischemic attack, or systemic embolism (126).